News on immunohistochemistry and other tissue-based testing methods.
The Boston-based company said it will use the funding in part to continue refining its artificial intelligence-powered pathology research platform.
The firm said that it will use the funding to support business activities to meet demand for its approach to clinical trial recruitment.
The companies anticipate providing services that combine Flagship’s biomarker development and Indivumed’s multiplex IHC assay development capabilities.
The device, called the MasSpec Pen, was developed by University of Texas researchers to help more quickly and accurately assess margins during cancer surgery.
The partnership will accelerate the development of molecular diagnostics in the Chinese market, Minneapolis-based Bio-Techne said.
